(Q28201003)

https://api.crossref.org/works/10.1034/J.1600-0404.2003.02049.X

27 December 2023

2

C Colosimo

0 references

Alberto Albanese

series ordinal

1

object named as

A. Albanese

1 reference

Europe PubMed Central

PubMed publication ID

12713527

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713527

full work available at URL

27 December 2023

language of work or name

English

0 references

publication date

May 2003

0 references

https://doi.org/10.1034/j.1600-0404.2003.02049.x

online access status

open access

1 reference

Europe PubMed Central

PubMed publication ID

12713527

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12713527

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1034%2Fj.1600-0404.2003.02049.x

27 December 2023

1 reference

https://api.crossref.org/works/10.1034/J.1600-0404.2003.02049.X

http://onlinelibrary.wiley.com/wol1/doi/10.1034/j.1600-0404.2003.02049.x/fullpdf

27 December 2023

1 reference

https://api.crossref.org/works/10.1034/J.1600-0404.2003.02049.X

Acta Neurologica Scandinavica

27 December 2023

published in

0 references

volume

107

0 references

issue

5

0 references

page(s)

349-55

0 references

cites work

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1034/J.1600-0404.2003.02049.X

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

21 April 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

3HDihydroergocryptine binding in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

Motor fluctuations in Parkinson's disease: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Clinical usefulness of apomorphine in movement disorders.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Dopamine receptors in the basal ganglia: relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Adverse effects of antiparkinsonian drugs

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Effect of dihydroergocryptine and dihydroergocristine on cyclic AMP accumulation and prolactin release in vitro: evidence for a dopaminomimetic action

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Pharmacokinetics of alpha-dihydroergocriptine in rats after single intravenous and single and repeated oral administrations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2003.02049.X

7 January 2021

Dihydroergocryptine in the Treatment of Parkinsonʼs Disease

series ordinal

24

1 reference

https://api.crossref.org/works/10.1034/J.1600-0404.2003.02049.X

27 December 2023

Identifiers